Format

Send to

Choose Destination
Bioorg Med Chem. 2011 Aug 1;19(15):4499-505. doi: 10.1016/j.bmc.2011.06.033. Epub 2011 Jun 16.

Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging.

Author information

1
Laboratory for Radiopharmacy, IMIR K.U. Leuven, O&N2, Herestraat 49, Bus 821, BE-3000 Leuven, Belgium.

Abstract

The type 2 cannabinoid receptor (CB₂R) is part of the endocannabinoid system and is expressed in tissues related to the immune system. As the CB₂R has a very low brain expression in non-pathological conditions, but is upregulated in activated microglia, it is an interesting target for visualization of neuroinflammation using positron emission tomography with a suitable radiolabeled CB₂R ligand. In this study, we radiolabelled a fluoroethyl derivative of GW405833, a well known CB₂R partial agonist, with fluorine-18 (half-life 109.8 min) by alkylation of the phenol precursor with 1-bromo-2-[¹⁸F]fluoroethane. In vitro studies showed that FE-GW405833 behaved as a selective high affinity (27 nM) inverse agonist for hCB₂R. [¹⁸F]FE-GW405833 showed moderate initial brain uptake in mice and rats, but a slow washout from brain and plasma due to retention of a radiometabolite. Specific binding of the tracer to human CB₂R was demonstrated in vivo in a rat model with local CB₂R overexpression in the brain. Optimized derivatives of GW405833 that are less susceptible to metabolism will need to be developed in order to provide a useful tracer for CB₂R quantification with PET.

PMID:
21737287
DOI:
10.1016/j.bmc.2011.06.033
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center